{"denoms":[{"counts":[{"groupId":"BG000","value":"345"},{"groupId":"BG001","value":"346"},{"groupId":"BG002","value":"343"},{"groupId":"BG003","value":"1034"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"BG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"BG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants received docetaxel 75 mg/m\\^2 IV over 1 hour Q3W for up to 2 years. Qualified participants who received docetaxel 75 mg/m\\^2 Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.","id":"BG002","title":"Docetaxel 75 mg/m^2"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.6","value":"62.1"},{"groupId":"BG001","spread":"9.7","value":"62.3"},{"groupId":"BG002","spread":"9.8","value":"61.6"},{"groupId":"BG003","spread":"9.7","value":"62.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"134"},{"groupId":"BG003","value":"399"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"213"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"209"},{"groupId":"BG003","value":"635"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"195"},{"groupId":"BG002","value":"191"},{"groupId":"BG003","value":"592"}],"title":"Weakly PD-L1 Positive"},{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"152"},{"groupId":"BG003","value":"442"}],"title":"Strongly PD-L1 Positive"}]}],"description":"PD-L1 expression was evaluated by immunohistochemistry (IHC) assay with a newly obtained tumor tissue with biopsy. If PD-L1 expression was observed in ≥1%, but ≤49% of tumor cells, a participant was categorized as weakly PD-L1 positive. If PD-L1 expression was observed in ≥50% of tumor cells, a participant was categorized as strongly PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Tumor Expression Status","unitOfMeasure":"Participants"}]}